Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Marketwired
192 Leser
Artikel bewerten:
(1)

True Leaf's 40-Acre Site Could Produce 125,000 Kilograms per Year -- CFN Media

SEATTLE, WA -- (Marketwired) -- 10/10/17 -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering True Leaf Medicine International Ltd.'s (CSE: MJ) (CNSX: MJ) (MJ.CN) (OTCQB: TRLFF) recently acquired option to purchase the 40 acres of land that encompass its facility in Lumby, B.C.

Canada's cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of recreational marijuana next year. Ontario's Finance Minister, Charles Sousa, warned that the demand could be so high that it would spark a shortage early on before licensed producers can pick up the slack. Health Canada has pledged to speed up its approval process, but it still takes up to a year for new producers to go live. Many existing licensed producers -- or late-stage applicants -- have responded by rapidly expanding their production capacity.

Once approved, True Leaf's existing facility would produce 2,500 kilograms per year and the 40-acre property would enable them to expand to a 1,000,000 square foot facility. This would put them at the high end of what many other licensed producers are currently targeting for production.

Company Name             Funded Sq. Ft.  Market Capitalization $CAN
Aphria Inc.                 1,000,000               $1B
Aurora Cannabis Inc.         895,000               $1.1B
Organigram Holdings Inc.     242,943               $310M

"This is a milestone for True Leaf," said CEO Darcy Bomford in a recent press release that described the newly optioned property and its potential within the market. "This property gives us the capacity to expand to meet the increased demand that is widely expected. With government approvals, the size of this site could allow us to build a 1,000,000 square foot facility and produce more than 125,000 kilograms of cannabis."

For more information on True Leaf's pending Regulation A+ offering, request the details at http://promo.cfnmedia.com/trueleaf.

Unique Among Competitors

True Leaf Medicine is unique among licensed producers in that it's dually-focused on cultivating cannabis for humans and producing hemp-based products for pets.

True Leaf Pets aims to capitalize on the $105 billion global pets market that includes $1.6 billion in spending on supplements and nutraceuticals. The company's soft chews are formulated with hemp and other active ingredients to support hip and joint health, calming, and immune and heart support in animals. The True Hemp™ products are fully legal in the U.S. and are already widely sold through the U.S., Canada, parts of Europe and New Zealand.

True Leaf Medicine is focused on cultivating medical marijuana under Canada's ACMPR program. After initially applying in July of 2013, the company is now at stage five of seven for its 32,000 square foot grow located on the 40-acre site. The company aims to be revenue-ready by next summer with the potential to generate upwards of $55 million per year at $8.80 per gram before factoring in its ambitious expansion plans.

Regulation A+ Offering

True Leaf Medicine is also unique in that it's among the first cannabis companies to raise capital under Regulation A+ in the United States and Canada, and it's perhaps the only Regulation A+ raise from a cannabis company selling legal products in both the US and Canada. The team is seeking to raise C$10 million through the offering to grow revenue at True Leaf Pet and advance its efforts to become a licensed producer in Canada under True Leaf Medicine. Regulation A+ makes it easy for anyone to purchase the company's securities with a C$250 minimum.

For more information on True Leaf's pending Regulation A+ offering, request the details at http://promo.cfnmedia.com/trueleaf.

Please follow the link to read the full article: http://www.cannabisfn.com/true-leafs-40-acre-site-produce-125000-kilograms-per-year/

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

SEC Disclaimer: An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that True Leaf Medicine Inc. may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement here. You should read the offering circular before making any investment.

No money or consideration is being solicited by the information on this website or any other communication and, if sent, money will not be accepted and will be promptly returned. No offer by a potential investor to buy our securities can be accepted and, if made, any such offer can be withdrawn before qualification of this offering by the SEC. A potential investor's indication of interest does not create a commitment to purchase the securities we are offering. Any such indication of interest may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance is given and all other requirements to accept an investment from a potential investor are met after the offering qualification date.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 Marketwired
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.